Posters

Title Date Documents

8th Annual Investing for Cures Forum Presentation

RXi Q2 2017 Earnings Conference Call Transcript

Marcum MicroCap Conference Presentation

Self-Delivering RNAi (sd-rxRNA®) Technology in Immuno-Oncology – Presented at: 3rd Annual Immuno-Oncology BD&L and Investment Forum

RXi Q1 2017 Earnings Conference Call Transcript

2016 Annual Report

A Phase 1/2 Multidose, Dose Escalation Study to Evaluate RXI-109 Administered by Intravitreal Injection to Reduce the Progression of Subretinal Fibrosis in Subjects with Advanced Neovascular AMD (NVAMD) #3210

Targeting Immune Checkpoints Using Self-Delivering RNAi (sd-rxRNA) Technology - Presented at: Cavendish Global Impact Forum

Targeting Immune Checkpoints Using Self-Delivering RNAi (sd-rxRNA®) Technology - Presented at: TIDES

Prevention of UVR Induced MMP1 Upregulation-MMP1 Targeting sd-rxRNA May Reduce the Effects of Skin Photo-aging - Presented at Society of Investigative Dermatology